Actnowfordiabetes
14/11/2022
Latest News
21,900
employees
150
countries in which the
Group’s medicines are distributed
20％
Over 20% of revenue from
brand-name medicines invested
in R&D each year
€ 5.3 billion
euros in revenue in 2022/2023
including €4 billion for brand-name medicines and
€1.3 billion for generic activities
4 therapeutic areas
Oncology, Neuroscience,
Immuno-inflammation,
and Cardiometabolism